Business
Pulse Biosciences to Participate in the Cowen Health Care Conference
HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company, today announced plans to participate in the
About this update from Pulse Biosciences, Inc
[{"type":"text","content":" HAYWARD, Calif.--(BUSINESS WIRE)--\nPulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company, today announced plans to participate in the upcoming Cowen Health Care Conference in Boston, Massachusetts.\n\n\nManagement is scheduled to present Tuesday, March 3, 2020 at 9:20am ET. Interested parties may access a live and recorded webcast on the “Investors” section of the company’s website at www.pulsebiosciences.com.\n\n\nAbout Pulse Biosciences\n\n\nPulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve and extend the lives of patients. If cleared, the CellFX® System will be the first commercial product to harness the distinctive advantages of the Company’s proprietary Nano-Pulse Stimulation™ (NPS™) technology to treat a variety of applications for which an optimal solution remains unfulfilled. NPS technology delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. As a multi-application platform, the CellFX System is intended to offer customer value with a utilization-based revenue model across an expanding spectrum of clinical applications. Subject to regulatory approval, the initial commercial use is expected to be in the clearance of common and difficult-to-treat skin lesions that share high demand among patients and practitioners for improved and durable aesthetic outcomes that could lead to greater overall satisfaction.\n\n\nPulse Biosciences, CellFX and Nano-Pulse Stimulation are registered trademarks of Pulse Biosciences, Inc.\n\n\nCaution: Pulse Biosciences’ CellFX System and Nano-Pulse Stimulation (NPS) technology are for investigational use only.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20200219005964/en/\n\nInvestors:\nPulse Biosciences\nSandra Gardiner, EVP and CFO\n510.241.1077\[email protected]\nor\nGilmartin Group\nPhilip Trip Taylor\n415-937-5406\[email protected]\n\n\nMedia:\nTosk Communications\nNadine D. Tosk\n504.453.8344\[email protected]\n\nSource: Pulse Biosciences, Inc.","length":3890,"tagName":"div"}]